Join Iterum Therapeutics at the Maxim Healthcare Summit
Join Iterum Therapeutics at the Maxim Healthcare Summit
DUBLIN and CHICAGO — Iterum Therapeutics plc (NASDAQ: ITRM), a clinical-stage pharmaceutical company dedicated to pioneering next-generation oral antibiotics, will participate in the 2024 Maxim Healthcare Virtual Summit. The conference aims to highlight advancements in combating infections caused by multi-drug resistant pathogens.
What to Expect at the Conference
On October 16, 2024, Corey Fishman, the CEO of Iterum, will engage in an insightful Fireside Chat with Jason McCarthy, Ph.D., the Senior Managing Director and Head of Biotechnology Research at Maxim Group. This discussion will begin at 10:00 a.m. ET and will provide attendees unique insights into the innovative approaches Iterum Therapeutics is taking to address critical healthcare challenges.
Conference Details
The Maxim Healthcare Summit is scheduled from October 15 to 17, 2024, and will be streamed live on M-Vest, allowing healthcare professionals and investors to engage with key players in the industry.
Understanding Iterum Therapeutics' Vision
Iterum Therapeutics focuses on developing differentiated anti-infectives that effectively tackle the pressing issue of multi-drug resistance, which poses a significant threat to public health globally. The company is driven by a mission to enhance the quality of life for those facing serious and often life-threatening infections.
Advancements in Antibiotic Development
Among its leading projects, Iterum is advancing sulopenem, an innovative penem anti-infective compound. This medication is available in both oral and intravenous formulations and has shown remarkable efficacy against a broad spectrum of bacteria, including gram-negative and gram-positive strains resistant to existing antibiotics.
Regulatory Progress and Future Outlook
Recently, Iterum Therapeutics has submitted a New Drug Application (NDA) for oral sulopenem aimed at treating uncomplicated urinary tract infections in adult women. The U.S. Food and Drug Administration has accepted this application for review, which is a significant milestone for the company. Notably, sulopenem has been granted Qualified Infectious Disease Product (QIDP) and Fast Track designations, enhancing its development priority across multiple indications.
Stay Connected with Iterum Therapeutics
For more details about Iterum Therapeutics and its ongoing projects, interested parties can visit their official website. Engaging in the summit will also provide further context on the company's upcoming innovations and their commitment to addressing urgent health issues.
Investor Relations for Iterum Therapeutics
Judy Matthews, the Chief Financial Officer, is the point of contact for investors seeking more information. The team encourages prompt inquiries and aims to provide comprehensive support regarding potential investments or insights into the organization’s strategic goals.
Frequently Asked Questions
What is Iterum Therapeutics known for?
Iterum Therapeutics is recognized for developing next-generation oral antibiotics targeting infections caused by multi-drug resistant pathogens.
When will Iterum's Fireside Chat take place?
The Fireside Chat will occur on October 16, 2024, at 10:00 a.m. ET during the Maxim Healthcare Virtual Summit.
What is the role of sulopenem in Iterum's portfolio?
Sulopenem is Iterum's leading anti-infective compound, designed to treat various bacterial infections with proven efficacy against resistant strains.
How can investors contact Iterum Therapeutics?
Investors can reach out to Judy Matthews, the CFO, at 312-778-6073 or via email at IR@iterumtx.com for inquiries.
Where can I find more information about the summit?
Details about the Maxim Healthcare Virtual Summit can be accessed by registering on M-Vest's platform prior to the event.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.